1. Scrip
  2. >>Therapy Areas

J&J Interested In ‘Differentiated’ Obesity Assets

 
• By Jessica Merrill

“It would be an area of interest to us,” Johnson & Johnson CEO Joaquin Duato said of the obesity space during the Morgan Stanley Healthcare Conference.

J&J building
Johnson & Johnson CEO Duato discussed M&A strategy • Source: Shutterstock

Johnson & Johnson is not ruling out being a late entrant into the obesity space. During an appearance at the Morgan Stanley Healthcare Conference on 4 September, CEO Joaquin Duato said the company is interested in obesity – but it would have to develop a differentiated product.

Key Takeaways
  • J&J CEO Joaquin Duato discussed M&A strategy during the Morgan Stanley Healthcare Conference.

“If we were able to identify assets in obesity that were sufficiently differentiated, it would be an area of interest...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.